A redox-coupled ROMO1–LONP1–SIRT3 axis controls hepatic lipid catabolism
Disturbed balance between lipid anabolism and catabolism drives hepatic steatosis. Mitochondria play a central role in lipid clearance through free fatty acid (FFA) oxidation, yet the molecular mechanisms governing this metabolic process remain incompletely understood. Here, we establish ROMO1, a recently identified mitochondrial thiol-protector, as a critical regulator of mitochondrial FFA oxidation through the LONP1–SIRT3 signaling axis. Hepatocyte-specific ablation of ROMO1 impairs mitochondrial FFA oxidation and causes hepatic lipid accumulation. Mechanistically, ROMO1 loss induces sulfenylation of the mitochondrial protease LONP1, resulting in excessive degradation of SIRT3 and consequent hyperacetylation of mitochondrial proteins involved in FFA oxidation. Importantly, ROMO1 overexpression protects against hepatic steatosis and liver injury by suppressing LONP1 sulfenylation and preserving SIRT3 protein stability in multiple mouse models of steatotic liver disease, whereas ROMO1 deficiency exacerbates disease progression. Moreover, spontaneous fatty liver in aged rhesus macaques is associated with reduced ROMO1 expression and concomitant loss of SIRT3 protein. Collectively, our findings establish the ROMO1–LONP1–SIRT3 axis as a redox-coupled signaling cascade that links mitochondrial redox regulation to hepatic lipid catabolism, providing potential therapeutic targets for steatotic liver diseases. Peng et al. demonstrate a critical role for the ROMO1–LONP1–SIRT3 signaling axis in protecting against hepatic steatosis and liver injury. By preventing LONP1 sulfenylation and the resultant SIRT3 degradation, ROMO1 promotes hepatic lipid catabolism.
Authors
- Xiaotao Duan (ORCID: https://orcid.org/0000-0001-9962-1234)
- Yanru Wang (ORCID: https://orcid.org/0000-0001-8838-0893)
- Heping Cheng (ORCID: https://orcid.org/0000-0002-9604-6702)
- Yuchen Ren (ORCID: https://orcid.org/0000-0002-6009-6118)
- Shan Qiu (ORCID: https://orcid.org/0000-0001-5091-4351)
- Wenlong Zhang (ORCID: https://orcid.org/0000-0002-3362-179X)
- Xianhua Wang (ORCID: https://orcid.org/0000-0002-2016-9415)
- Fengli Xu (ORCID: https://orcid.org/0009-0008-4628-5378)
- Kun Peng (ORCID: https://orcid.org/0009-0003-8856-3632)
- Ling Fu (ORCID: https://orcid.org/0000-0003-2071-9189)
- Xiuqin Zhang
- Yan Xu
Institutions
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Peking University (CN)
- Beijing Proteome Research Center (CN)
- Center for Life Sciences (CN)
- State Key Laboratory of Membrane Biology (CN)
- State Key Laboratory of Proteomics (CN)
Publication Details
- Journal
- Nature Communications
- Published
- 2026-11-16
- DOI
- https://doi.org/10.1038/s41467-026-79334-7
- Primary Topic
- Liver Disease Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China
- Peking University